CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis

Abstract

Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-β-treated patients, we found that the hazard ratio for developing an attack was 2.8 in patients with CD26+CD4+T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-β antibodies. CD26+CD4+T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-β.

Keywords

CCR5 antigen CD25 antigen CD26 antigen interferon treatment multiple sclerosis T cell immunology treatment response

Get full access to this article

View all access options for this article.

References

Sorensen PS , Ross C , Clemmesen KM , Bendtzen K , Frederiksen JL , Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsingremitting multiple sclerosis . Lancet 2003; 362: 1184-1191 .

Khoury SJ , Guttmann CRG , Orav EJ , Kikinis R , Jolesz FA , Weiner HL et al. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis . Arch Neurol 2000; 57: 1183-1189 .

Sørensen TL , Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS . Neurology 2001; 57: 1371-1376 .

Sørensen TL , Ransohoff RM , Jensen J , Sellebjerg F. Evidence favoring the involvement of CC chemokine receptor (CCR) 5 in T-lymphocyte accumulation in optic neuritis . Acta Neurol Scand 2003; 107: 221-227 .

Jensen J , Langkilde AR , Fenst C , Nicolaisen MS , Roed HG , Christiansen M et al. CD4 T cell activation at onset of multiple sclerosis . J Neuroimmunol 2004; 149: 202-209 .

Viglietta V , Baecher-Allan C , Weiner HL , Hafler D. Loss of functional suppression by CD4+CD25+regulatory T cells in patients with multiple sclerosis . J Clin Invest 2004; 199: 971-979 .

Reinhold D , Hemmer B , Gran B , Born I , Faust J , Neubert K et al. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones . J Neuroimmunol 1998; 87: 203-209 .

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci USA 1999; 96: 6873-6878 .

Sorensen TL , Tani M , Jensen J , Pierce V , Lucchinetti C , Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients . J Clin Invest. 1999; 103: 807-815 .

10.

Sellebjerg F , Madsen HO , Jensen J , Garred P. CCR5 D32, matrix metalloproteinase-9 and disease activity in multiple sclerosis . J Neuroimmunol 2000; 102: 98-106 .

11.

Kantor R , Bakhanashvili M , Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS . Neurology 2003; 61: 238-240 .

12.

Ross C , Clemmesen KM , Svenson M , Sorensen PS , Koch-Henriksen N , Skovgaard GL et al. Immunogenicity of inter-feron-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration . Ann Neurol 2000; 48: 706-712 .

13.

Bielekova B , Martin R. Development of biomarkers in multiple sclerosis . Brain 2004; 127: 1463-1478 .

14.

Lublin FD , Baier M , Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis . Neurology 2003; 61: 1528-1532 .

15.

Stü rzebecher S , Wandinger KP , Rosenwald A , Sathyamoorthy M , Tzou A , Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-b in multiple sclerosis . Brain 2003; 126: 1419-1429 .

16.

Wandinger K-P , Lü nemann, Wengert O , Bellmann-Strobl J , Aktas O , Weber A et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis . Lancet 2003; 361: 2036-2043 .

17.

Batocchi AP , Rotondi M , Caggiula M , Frisullo G , Odoardi F , Nociti V et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta . J Neuroimmunol 2003; 139: 150-154 .